An investigation on behalf of investors in Kezar Life Sciences, Inc. (NASDAQ: KZR) shares over potential wrongdoing at Kezar Life Sciences, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 10/18/2019 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kezar Life Sciences, Inc.
Investors who purchased shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) and currently hold any of those NASDAQ: KZR shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Kezar Life Sciences, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Kezar Life Sciences, Inc. went public in June 2018 and sold 5 million shares at $15 per share.
Since then, shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) declined to as low as $2.88 per share on October 2, 2019.
Those who purchased shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in conftact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels